NanoViricides, Inc. (NYSE American: NNVC) announced it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo (DRC) in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company stated that site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.
The trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. Importantly, the company noted that NV-387, a broad-spectrum antiviral candidate, has also been proposed for evaluation against Ebola virus infections. The shipment makes the drug locally available should it be utilized in response efforts, highlighting its potential as a versatile therapeutic.
NanoViricides believes successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola. This is particularly significant given the ongoing MPox outbreak in the DRC and the need for effective treatments against emerging viral threats. The broad-spectrum nature of NV-387, which targets a range of viruses including RSV, COVID-19, Influenza, and MPox, underscores its potential impact on public health.
The company’s lead drug candidate, NV-387, is a nanoviricide designed to treat respiratory viral infections and other diseases. The Phase II trial in the DRC represents a critical step in clinical development, and if successful, could pave the way for regulatory approvals and broader use. The move also demonstrates NanoViricides' commitment to addressing global health challenges, particularly in regions with high disease burden.
For more details, the full press release is available at https://ibn.fm/CTIZc. Additional updates on NanoViricides can be found in the company’s newsroom at https://ibn.fm/NNVC.
